electronRx

Executive Summary

electronRx is a Cambridge-based digital health company pioneering clinically validated digital biomarkers and continuous monitoring platforms for respiratory diseases including COPD, asthma, interstitial lung disease, and pulmonary hypertension. By leveraging wearable sensors and AI-driven analytics, the company enables real-time patient insights, early detection of exacerbations, and robust endpoint generation for clinical trials. Its technology addresses critical pain points in respiratory drug development: it improves patient stratification, reduces protocol deviations, and generates real-world evidence that can accelerate regulatory approvals and differentiate therapies in a competitive market. Founded in 2020, electronRx has grown to a team of 50-200 employees and operates at the platform stage, indicating an established product ready for scaling through partnerships with pharmaceutical companies and contract research organizations. The company's core value lies in transforming subjective patient-reported outcomes into objective, continuous digital endpoints that enhance the precision and efficiency of clinical trials. With increasing regulatory acceptance of digital health technologies and growing investment in remote monitoring solutions, electronRx is well-positioned to capture a significant share of the respiratory digital biomarker market. Success will hinge on its ability to secure strategic collaborations, expand its evidence base through peer-reviewed publications, and achieve regulatory clearances or certifications. The addressable market spans the respiratory therapeutics pipeline, where sponsors seek ways to reduce trial costs, improve data quality, and bring differentiated products to patients faster.

Upcoming Catalysts (preview)

• Q3 2026Pharmaceutical Partnership for COPD or Asthma Clinical Trial60% success
• Q4 2026Series A or B Funding Round50% success
• Q1 2027FDA 510(k) Clearance or CE Mark for Digital Monitoring Platform40% success